The AMSP drug safety program:: Methods and global results
The AMSP drug safety program:: Methods and global results
复制标题
DOI：
10.1055/s-2004-815505
复制
发表时间：
2004-03-01
影响因子：
4.3
通讯作者：
Hippius, H
中科院分区：
文献类型：
--
作者：
Grohmann, R;Engel, RR;Hippius, H
AMSP（Arzneimittelsicherosin der Psychiatry）研究是一项药物安全性项目，旨在确保在常规临床治疗的自然条件下持续评估精神科住院患者的严重药物不良反应（ADR）。它是由之前的药物监测研究AMUP（精神病学中的Arzneimitteluberwachung）发展而来的。目前有35家医院参与了这项研究。本文介绍了AMSP的方法，给出了评估为“严重”的ADR的详细定义，并讨论了这些定义的含义和评估AMSP数据的方法。此外，还提供了1993年至2000年关于ADR发生率的一些总体数据。
The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions Of routine clinical treatment. It developed out of the preceding drug surveillance study AMUP (Arzneimitteluberwachung in der Psychiatrie). Currently 35 hospitals participate in the Study. This paper describes the methods of the AMSP, gives detailed definitions of ADRs assessed to be "severe," and discusses the implications of these definitions and the methodological approach for evaluating the AMSP data. In addition, some overall data compiled on ADR rates from 1993 to 2000 are given.